Strict control of drug abuse, comprehensive upgrade of the regulation of addictive drugs such as Pravabalin and Yumei preparations.

Today, the reporter learned from the National Medical Products Administration that a joint announcement has been issued by the National Medical Products Administration, the Ministry of Public Security, and the Office of the National Narcotics Control Committee, aimed at further strengthening the supervision of addictive drugs such as Prunabalin oral formulations and Yumei formulations along the entire chain, in order to firmly curb the trend of drug abuse. The latest announcement focuses on the production, distribution, and retail of drugs like Prunabalin, implementing strict control measures. The National Medical Products Administration has requested provincial medical products authorities to strictly implement production plans to reduce the risk of abuse at the source. At the same time, it will comprehensively regulate purchasing and sales activities, prohibit online or disguised retail sales of related drugs, and require physical retail outlets to sell products through designated counter, staff, and strict prescription requirements. Purchase and sales records will be managed in a dedicated ledger, including information such as the name of the drug, specifications, sales quantity, manufacturer, batch number, purchase date, name and ID of the buyer.